FAG
CRSP icon

Fortitude Advisory Group’s CRISPR Therapeutics CRSP Stock Holding History

Fortitude Advisory Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-51
Closed -$3K – 433
2022
Q1 		$3K Sell
51
-100
-66% -$6.28K ﹤0.01% 1256
2021
Q4 		$12K Buy
+151
New +$13.2K 0.01% 979

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fortitude Advisory Group's CRSP Position: Q2 2022 in Review

Fortitude Advisory Group sold out of CRISPR Therapeutics (CRSP) in Q2 2022, closing a stake of 51 shares — an estimated $3K sold.

Fortitude Advisory Group first reported a position in CRSP in Q4 2021 and held it in 2 quarters. The position peaked at $12K in Q4 2021. 435 funds tracked by Wall St. Rank hold CRSP as of Q2 2022.

  • Fortitude Advisory Group reported no remaining CRISPR Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Fortitude Advisory Group sold 51 CRISPR Therapeutics shares in Q2 2022, an estimated $3K.
  • Fortitude Advisory Group first reported a position in CRISPR Therapeutics in Q4 2021 and held it in 2 quarters.
  • Fortitude Advisory Group's CRISPR Therapeutics position peaked at $12K in Q4 2021.
  • 435 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2022.

Based on Fortitude Advisory Group's 13F filing for Q2 2022, filed 16 Aug 2022.